Mydecine Provides Q4 2023 Business Update
October 26, 2023 02:00 ET | Mydecine Innovations Group Inc.
Mydecine is pleased to address its shareholders and provide a general update on the company's progress.
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
October 16, 2023 08:11 ET | Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
Change from Baseline in CAPS-5 Total Symptom Severity Scores
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
September 28, 2023 06:00 ET | Bionomics Ltd
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
September 27, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer...
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 20, 2023 08:28 ET | Silo Pharma, Inc.
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
September 14, 2023 06:00 ET | Bionomics Ltd
Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s DiseaseBased on the learnings from Bionomics’ candidate BNC375,...
Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
August 23, 2023 06:00 ET | Bionomics Ltd
The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSDTopline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected...
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
August 08, 2023 08:00 ET | Incannex Healthcare
Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3...
Texans Pup
August 02, 2023 12:07 ET | Guide Dog Foundation
Smithtown, New York, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Today, America’s VetDogs, a national nonprofit that trains and places service dogs with veterans and first responders with disabilities, in...
Quarterly Activities and Cashflow Report
July 31, 2023 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, and CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company...